Joseph Todisco compensation by year
CorMedix Summary Compensation Table · all 4 fiscal years held| Component | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Salary | $378,461 | $616,962 | $639,214 | $684,353 |
| Bonus | $0 | $0 | $0 | $0 |
| Stock awards | $701,245 | $0 | $462,666 | $4,492,500 |
| Option awards | $1,273,500 | $1,388,400 | $745,788 | $0 |
| Non-equity incentive | $305,760 | $401,700 | $457,335 | $865,072 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 |
| All other | $32,223 | $52,370 | $54,906 | $59,251 |
| Total | $2,691,189 | $2,459,342 | $2,359,908 | $6,101,176 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CorMedix Inc. DEF 14A filed April 29, 2026, accession 0001213900-26-049311, and prior-year filings. Open the filing on EDGAR.
How this page was built: the CorMedix Inc. filed document, accession 0001213900-26-049311. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 207,292 | $2,410,806 | — |
| PSU | 125,000 | $1,453,750 | — |
| RSU | 77,156 | $897,327 | — |
| Option | 125,000 | — | $3.38 |
| Option | 100,000 | — | $4.43 |
| Option | 133,334 | — | $3.47 |
Per the Outstanding Equity Awards at Fiscal Year-End table in CorMedix Inc.'s FY2025 proxy; value at the fiscal year-end close, as the company printed it.
Change-in-control & termination
estimated payments CorMedix discloses, by trigger · FY2025| Trigger | Cash severance | Accelerated equity | Benefits continuation | Total as disclosed |
|---|---|---|---|---|
| Involuntary termination without cause | $1,096,550 | $3,989,116 | $46,730 | $5,132,396 |
| Change in control and involuntary termination | $2,076,800 | $7,942,043 | $70,095 | $10,088,938 |
Per the Potential Payments Upon Termination or Change in Control table in CorMedix Inc.'s FY2025 proxy. Estimates as the company printed them; a dash means it printed no figure.
CorMedix’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Joseph Todisco · this page | Chief Executive Officer | $6,101,176 |
| Beth Zelnick Kaufman | Executive Vice President, Chief Legal/Compliance Officer & Corp. Secretary | $3,765,910 |
| Elizabeth Hurlburt | Executive Vice President, Chief Operating Officer | $3,743,688 |
Board service
CorMedix board · FY2021–FY2025How this board is paid
Company policy: CorMedix pays directors a $55,000 cash retainer. As stated in CorMedix's FY2025 proxy.
The full CorMedix compensation record
free company briefThis page is one person within CorMedix's record. The company brief lists every named executive, each linking to their own page.
Compensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order CorMedix's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CorMedix's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order CRMD
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.